Clinical trials: DASATINIB
Multiple Myeloma
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560352
- Testing
- Dasatinib, Bortezomib, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP.
- Trial name
- NCT04971226
- Testing
- Imatinib, Nilotinib, Bosutinib
- Where
- 110 sites in United States, Australia and 27 more
- Volunteers
- 405 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
The purpose of this study is assess the effects of the investigational drug dasatinib on participants who are in chronic phase Philadelphia chromosome chronic myeloid leukemia and who are either resistant to or intolerant of…
- Trial name
- NCT00101660
- Testing
- Dasatinib
- Where
- 85 sites in United States, Australia and 20 more
- Volunteers
- 387 people
- Sponsor
- Bristol-Myers Squibb
Hematologic Malignancies, Adult
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198.
- Trial name
- NCT06645886
- Testing
- KQB198, Dasatinib
- Where
- 29 sites in United States, France and 6 more
- Volunteers
- 13 people
- Sponsor
- Kumquat Biosciences Inc.
Leukemia
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.
- Trial name
- NCT00978731
- Testing
- Dasatinib
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Leukemia
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
The purpose of this clinical research study was to establish a recommended phase 2 once daily (QD) dose of dasatinib and to assess the efficacy of the investigational drug for relapsed or refractory (resistant to previous…
- Trial name
- NCT00306202
- Testing
- Dasatinib
- Where
- 13 sites in Austria, France and 4 more
- Volunteers
- 63 people
- Sponsor
- Bristol-Myers Squibb
Leukemia
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study
This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days.
- Trial name
- PASS (NCT02546791)
- Testing
- Dasatinib
- Volunteers
- 101 people
- Sponsor
- Bristol-Myers Squibb
Pharmacokinetic Study in Healthy Participants
Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations
The purpose of the study is to compare the blood levels of dasatinib in healthy participants who received tablet formulation with those of healthy participants who received liquid and tablet-dispersed formulations of the drug.
- Trial name
- NCT01392703
- Testing
- Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets
- Where
- United States
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Leukemia, Myeloid, Chronic
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
The purpose of this study is to compare the efficacy of dasatinib with that of high-dose (800-mg) imatinib in participants with chronic phase chronic myeloid leukemia who achieved only a suboptimal response after at least 3…
- Trial name
- NCT00320190
- Testing
- Imatinib, Dasatinib
- Where
- 27 sites in Belgium, Finland and 9 more
- Volunteers
- 52 people
- Sponsor
- Bristol-Myers Squibb
Pharmacokinetics, Drug Interactions
Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions
In this open label, single-sequence study, subjects received one dose of XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation at the start of study on Day 1 and Day 6.
- Trial name
- NCT05433896
- Testing
- Dasatinib ASD, Omeprazole 40 MG
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Xspray Pharma AB
Chronic Myeloid Leukemia
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting
This is a prospective, non-interventional study conducted in CP-CML patients receiving dasatinib who are enrolled by a sample of hematologists in France.
- Trial name
- NCT04089839
- Testing
- Non-Interventional
- Where
- France
- Volunteers
- 177 people
- Sponsor
- Bristol-Myers Squibb
Myeloid Leukemia, Chronic, Chronic-Phase
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
CML requires ongoing treatment and assessment of treatment milestones in order to manage the disease properly. Dasatinib is approved for the treatment of newly diagnosed PH+ CP-CML and CML in chronic or accelerated phase or blast…
- Trial name
- DasPAQT (NCT02348957)
- Where
- 66 sites in Germany
- Volunteers
- 223 people
- Sponsor
- Onco Medical Consult GmbH
Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are…
- Trial name
- NCT00123487
- Testing
- dasatinib
- Where
- 119 sites in United States, Argentina and 30 more
- Volunteers
- 638 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myelogenous Leukemia
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
This study is composed of Phase I and Phase II part. Phase I part: The objective is to evaluate the safety of BMS-354825 in subject with chronic phase Chronic Myelogenous Leukemia (CML).
- Trial name
- NCT00337454
- Testing
- Dasatinib
- Where
- 21 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome…
- Trial name
- NCT00101595
- Testing
- Dasatinib
- Where
- 60 sites in United States, Argentina and 18 more
- Volunteers
- 96 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Breast Cancer
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
- Trial name
- NCT00696072
- Testing
- Dasatinib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Expanded Access for Dasatinib
This is an expanded access designed to provide access to dasatinib for eligible participants.
- Trial name
- NCT00454753
- Testing
- Dasatinib
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia (CML)
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
The purpose of this study was to determine how often and how likely patients are to develop Type 2 Diabetes or high cholesterol/lipids when receiving dasatinib or nilotinib as therapy for Chronic Myelogenous Leukemia (CML).
- Trial name
- NCT02733445
- Testing
- dasatinib, nilotinib
- Volunteers
- 2,650 people
- Sponsor
- Bristol-Myers Squibb
Liver Diseases
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
- Trial name
- NCT00382668
- Testing
- Dasatinib
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Glioblastoma
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma
- Trial name
- NCT00948389
- Testing
- Dasatinib, Lomustine
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 28 people
- Sponsor
- Bristol-Myers Squibb